Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.

After [losing out to Pfizer]( ...

Novo Nordisk, the 102-year-old Danish drugmaker behind the blockbuster drugs Ozempic and Wegovy, is laying off thousands of workers as it seeks to recoup some of the revenue it’s lost to competitors ...

Shares in Novo Nordisk and Eli Lilly slipped on Friday after both agreed with the U.S government to lower prices of their ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — Novo Nordisk, under new leadership and in need of a boost, said ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

LONDON (Reuters) -Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its ...

Novo Nordisk announced a restructuring plan to be implemented during the third quarter. Management lowered constant currency operating profit growth guidance for 2025 ...

Wegovy-maker Novo Nordisk will cut 9,000 jobs, or about 11.5% of its workforce, in a restructuring to save $1.26 billion annually, it said on Wednesday, as it battles rising pressure from US rival Eli ...